Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
56 studies found for:    "progressive supranuclear palsy"
Show Display Options
Rank Status Study
1 Completed Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
Condition: Progressive Supranuclear Palsy
Interventions: Drug: valproic acid;   Drug: Placebo
2 Completed Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Drug: Coenzyme Q10
3 Not yet recruiting A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: ABBV-8E12;   Drug: Placebo
4 Terminated Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: Rasagiline;   Drug: Sugar pill
5 Active, not recruiting Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: Single dose C2N-8E12;   Drug: Single dose placebo
6 Unknown  Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Drug: alpha-lipoic acid and L-acetyl carnitine
7 Completed Rehabilitation in Patients With Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Other: MIRT;   Other: MIRT+Lokomat
8 Recruiting Young Plasma Transfusions for Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Other: Fresh Frozen Plasma
9 Recruiting A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Drug: F-18 AV 1451
10 Recruiting A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Drug: Salsalate
11 Completed Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: Davunetide;   Drug: Placebo
12 Enrolling by invitation Extension Study of BMS-986168 in Patients With Progressive Supranuclear Palsy Who Participated in CN002003
Condition: Progressive Supranuclear Palsy
Intervention: Drug: BMS-986168
13 Active, not recruiting Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: BMS-986168;   Drug: Placebo
14 Completed A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.
Condition: Progressive Supranuclear Palsy
Interventions: Dietary Supplement: Pyruvate, creatine, niacinamide;   Dietary Supplement: Placebo
15 Completed Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: tideglusib;   Drug: placebo
16 Recruiting Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy (PSP)
Interventions: Drug: Rivastigmine;   Drug: Placebo
17 Completed Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
Conditions: Progressive Supranuclear Palsy;   Parkinson's Disease
Interventions: Device: active Deep TMS;   Device: sham Deep TMS
18 Unknown  Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism
Condition: Progressive Supranuclear Palsy
Intervention: Biological: stem cell therapy
19 Completed Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
Conditions: Progressive Supranuclear Palsy;   Atypical Parkinsonism
Intervention: Drug: CoenzymeQ10
20 Completed Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Intervention: Drug: GDNF & Synchro Med Infusion System

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.